Value Proposition

“This analysis provides a framework for providers and payers evaluating the cost-effectiveness of generic celecoxib given a range of discontinuation rates, toxicity rates, and drug costs,” said Elena Losina, PhD, and colleagues.

Dr Doshi and colleagues used the study sample to predict what costs would have been using the MedPAC proposals and found that for patients using specialty RA drugs, the OOP costs would remain front loaded into the beginning of the year, ranging from $512 to $1076 per month from January to May.

Results 1 - 2 of 2
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management